These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25252191)

  • 1. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.
    Zheng Q; Peskoe SB; Ribas J; Rafiqi F; Kudrolli T; Meeker AK; De Marzo AM; Platz EA; Lupold SE
    Prostate; 2014 Dec; 74(16):1655-62. PubMed ID: 25252191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.
    D'Antonio KB; Schultz L; Albadine R; Mondul AM; Platz EA; Netto GJ; Getzenberg RH
    Clin Cancer Res; 2010 Dec; 16(23):5908-13. PubMed ID: 21138874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
    PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy.
    Long Q; Johnson BA; Osunkoya AO; Lai YH; Zhou W; Abramovitz M; Xia M; Bouzyk MB; Nam RK; Sugar L; Stanimirovic A; Williams DJ; Leyland-Jones BR; Seth AK; Petros JA; Moreno CS
    Am J Pathol; 2011 Jul; 179(1):46-54. PubMed ID: 21703393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.
    Melbø-Jørgensen C; Ness N; Andersen S; Valkov A; Dønnem T; Al-Saad S; Kiselev Y; Berg T; Nordby Y; Bremnes RM; Busund LT; Richardsen E
    PLoS One; 2014; 9(11):e113039. PubMed ID: 25401698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
    Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
    Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
    Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy.
    Blum DL; Koyama T; M'Koma AE; Iturregui JM; Martinez-Ferrer M; Uwamariya C; Smith JA; Clark PE; Bhowmick NA
    Clin Cancer Res; 2008 Dec; 14(23):7790-7. PubMed ID: 19047106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.
    Leite KR; Tomiyama A; Reis ST; Sousa-Canavez JM; Sañudo A; Camara-Lopes LH; Srougi M
    Urol Oncol; 2013 Aug; 31(6):796-801. PubMed ID: 21880514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-21, miR-221 and miR-222 expression and prostate cancer recurrence among obese and non-obese cases.
    Amankwah EK; Anegbe E; Park H; Pow-Sang J; Hakam A; Park JY
    Asian J Androl; 2013 Mar; 15(2):226-30. PubMed ID: 23353719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.
    Loeb S; Folkvaljon Y; Robinson D; Schlomm T; Garmo H; Stattin P
    Eur Urol; 2016 Nov; 70(5):824-828. PubMed ID: 26743040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?
    Nordby Y; Richardsen E; Ness N; Donnem T; Patel HRH; Busund LT; Bremnes RM; Andersen S
    Sci Rep; 2017 Nov; 7(1):16308. PubMed ID: 29176717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy.
    Wei W; Leng J; Shao H; Wang W
    Am J Med Sci; 2017 Apr; 353(4):315-319. PubMed ID: 28317618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
    Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
    Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens.
    De Marzo AM; Knudsen B; Chan-Tack K; Epstein JI
    Urology; 1999 Apr; 53(4):707-13. PubMed ID: 10197845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.